Weight boss? Competition for Novo Nordisk
Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm’s success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most,…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Economist Podcasts →
Novo Nordisk hits back at copycat drugs
Novo Nordisk, Eli Lilly and the GLP-1 economy
The Weight Loss Drug Revolution: Transforming Bodies and Reshaping Economies | The Global Brief
Can weight loss drugs reduce healthcare costs?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.